



**FOR IMMEDIATE RELEASE**

May 1, 2025

Listed Company Name:	Eisai Co., Ltd.
Representative:	Haruo Naito Representative Corporate Officer and CEO
Securities Code:	4523
Stock Exchange Listings:	Prime Market of the Tokyo Stock Exchange
Inquiries:	Teruyuki Masaka Vice President, Corporate Communications Phone +81-3-3817-5120

**REVENUE OF LEQEMBI® (PRELIMINARY BASIS)**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI®" (generic name: lecanemab) was JPY 14.7 billion for the fourth quarter of fiscal year 2024 (January 1, 2025 – March 31, 2025) and JPY 44.3 billion for the full fiscal year 2024 (April 1, 2024 – March 31, 2025).

This information is being disclosed in conjunction with today's announcement of the financial results for the first quarter of 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai's financial results for the fiscal year 2024, including details of LEQEMBI's revenue, will be disclosed in Eisai's financial disclosure scheduled for May 15, 2025.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.

\*\*\*